Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia’s Yutrepia drug treating adults with pulmonary diseases. The delay has been referred to as a “curveball scenario” by Needham, as the drug was expected to be approved for launch by 4Q24.
| Ticker Symbol | Company Name | Join Deadline | Join |
|---|---|---|---|
| WOLF | Wolfspeed, Inc. | January 17, 2025 | Join |
| SUI | Sun Communities, Inc. | February 10, 2025 | Join |
| SAVA | Cassava Sciences, Inc. | February 10, 2025 | Join |
| APLT | Applied Therapeutics, Inc. | February 18, 2025 | Join |
| BIOA | BioAge Labs, Inc. | March 10, 2025 | Join |
| PCRX | Pacira BioSciences, Inc. | March 14, 2025 | Join |